Mitsugu Kanehira

Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling

Ryo Takata, Toyomasa Katagiri, Mitsugu Kanehira et al. · Clinical Cancer Research · 2005 · 240 citations

Bladder Cancers, Engineering, Cisplatin Neoadjuvant Chemotherapy +21

Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis

Mitsugu Kanehira, Yosuke Harada, Ryo Takata et al. · Oncogene · 2007 · 109 citations · Full text

Urology, Genitourinary Cancer, Medicine +6

Oncogenic Role of MPHOSPH1, a Cancer-Testis Antigen Specific to Human Bladder Cancer

Mitsugu Kanehira, Toyomasa Katagiri, Arata Shimo et al. · Cancer Research · 2007 · 106 citations

Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells

Yosuke Harada, Mitsugu Kanehira, Yoshiko Fujisawa et al. · Cancer Research · 2010 · 99 citations

Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy

Ryo Takata, Toyomasa Katagiri, Mitsugu Kanehira et al. · Cancer Science · 2006 · 71 citations · Full text